Guidelines for Serum Cholesterol and LDL-C Levels

Risk-Based Approach to LDL-C Management

The American College of Cardiology and the American Heart Association recommend that the decision to initiate statin therapy should be based on both LDL-C levels and cardiovascular risk assessment, with lifestyle modifications recommended for all patients with elevated LDL-C regardless of whether medication is indicated 1, 2
For high-risk patients, the LDL-C goal is <100 mg/dL, and for very high-risk patients, the LDL-C goal of <70 mg/dL is reasonable 4, 5
The American College of Cardiology recommends starting statin therapy simultaneously with lifestyle therapy when LDL-C ≥100 mg/dL 1, 2
For patients with LDL-C between 100-129 mg/dL, statin therapy is recommended along with lifestyle modifications 1, 2, 5

The American Diabetes Association recommends considering Mediterranean or DASH eating patterns, and reducing trans fat intake and increasing plant stanols/sterols and n-3 fatty acids 5
Weight loss of 5-10% can significantly improve lipid profiles in overweight/obese individuals 5

For diabetes patients aged 40-75 years with additional ASCVD risk factors, the American Diabetes Association recommends high-intensity statin therapy to reduce LDL-C by ≥50% and target LDL-C <70 mg/dL 5
The American Diabetes Association recommends intensifying lifestyle therapy and optimizing glycemic control for patients with elevated triglycerides and/or low HDL-C 5

The American College of Cardiology recommends reassessing lipid profile after 6-12 weeks of therapy, and monitoring liver enzymes as clinically indicated when on statin therapy 3

The American College of Cardiology and the American Heart Association recommend calculating 10-year ASCVD risk before making treatment decisions, and considering combination therapy for high-risk patients who fail to reach LDL-C goals with statin monotherapy 1, 2, 5
The American College of Cardiology recommends addressing other modifiable risk factors (smoking, hypertension, diabetes) that contribute to overall cardiovascular risk 4